Ethocle Reports has published its latest Market Research Report on Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022. Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies. Browse market data tables and figures.

1. Anti-hypertensive TherapeuticsinAsia-PacificMarketsto2022 - Increasing Prevalence of
HypertensionDrivesMarket Growth despite WeakPipeline
Ethocle Reportshaspublished its latest MarketResearch Reporton Anti-hypertensiveTherapeuticsin
Asia-PacificMarkets to 2022. Understand thecurrentclinical and commercial landscapeby considering
diseasepathogenesis,diagnosis,prognosis,and thetreatmentoptionsavailableateach stageof
diagnosis,including a clinical comparison of marketed therapies. Browsemarketdata tablesand figures.
PublishedOn:01-Dec-2016 | Pages:110
Summary
Hypertensionisaseriousandcommonmedical conditioncharacterizedbyelevatedbloodpressure.Itis
commonlyseeninthe agingpopulation,andinpeople withsedentarylifestylesandobesity.Asone of
the most significantpreventablecausesof deathworldwide,early diagnosisof the conditioniscrucial to
improve healthoutcomes.Hypertensionisthe keyriskfactorforstroke;accordingto the National
Stroke Association(NSA),two-thirdsof patientswhosufferastroke have hypertension.
Hypertensionitself doesnotmanifestanysymptoms,butdirectdamage canoccur to variousorgansdue
to highbloodpressure.Incasesof hypertensive emergency(where bloodpressureishigherthan
180/110mmHg) patientshave reportedheadaches,breathlessnessormalaise due toheartfailure and
kidneyfailure.Whethersymptomaticorasymptomatic,hypertensionrequiresattentionandappropriate
changesinlifestyle ormedical treatment
The marketedproductslandscape forhypertensioncomprisesawide range of treatmentoptions,which
includesangiotensinconvertingenzyme inhibitors,angiotensinreceptorblockers,calciumchannel
blockers,betablockers,renininhibitors,anddiuretics.These are usedbothasmonotherapyand
combinationtherapy(includingfixed-dose combinations),andthe proportionof patientstreatedusing
the varioustherapyapproachesvariesfromcountrytocountry.
The highprevalence of the disease isasubstantial contributortohealthcare costsandisa majorcause
of morbidity.However,awarenessof hypertensionislow amongphysicians,patients,andthe public,
leadingtoa highlevel of undiagnosedanduntreatedcases.
Click here to find out more about this report?

2. Scope
The Asia-Pacificantihypertensive marketwill be valuedat$27 billionin2022, growingfrom$19.1 billion
in2015 at a CAGR of 5.1%. Hypertensionprevalence isaprominentcontributortomarketsize inthe
assessedcountries.The marketismostlydominatedbygenerics,andthere are onlyafew patented
products.
- Will genericscontinue todominate treatment?
- How do the elderlypopulationsandtheirassociatedriskfactorsaffectprevalence?
- What effectwill the patentexpirationsof currentlybrandedtherapieshave onmarketvalue?
The current anti-hypertensivetherapeuticspipeline isweak,comprising112 moleculesinvariousstages
of development,dominatedbysmall molecules.
- Which moleculartargetsappearmostfrequentlyinthe pipeline?
- Is there potential forthe pipelinetoaddressunmetneedswithinthe anti-hypertensive market?
Analysisof clinical trialssince2006 identifiedthatanti-hypertensiveproductshave ahighrate of
attrition.
- How do failure ratesvarybyproduct stage of development,molecule type,andmechanismof action?
- How do otherfactors suchas average trial duration andtrial size influence the costsandrisks
associatedwithproductdevelopment?
The market forecastsindicate thatJapanwill contributethe mosttothe Asia-Pacificmarketvalue,due
to the highannual cost of therapy.Growthinmarketsize isprojectedtovaryconsiderablyacrossthe
five assessedmarkets.
- How will the annual costof therapyandmarketsize varybetweenthe five Asia-Pacificmarkets?
- How couldchangesinrisk factorssuch as agingpopulation,metabolicdisordersandhighsaltintake
influencethe market?
- Variousdriversandbarrierswill influence the marketoverthe forecastperiod.
- What are the barriersthat limitthe uptake of premium-pricedtherapeuticsinthe assessedcountries?
- Which factorsare most likelytodrive the marketinthese countries?
Get Free Sample Report

3. Click here for Discounts
Reasons to buy
Thisreportwill allowyouto -
- Understandthe currentclinical andcommercial landscape byconsideringdiseasepathogenesis,
diagnosis,prognosis,andthe treatmentoptionsavailable ateachstage of diagnosis,includingaclinical
comparisonof marketedtherapies.
- Visualizethe compositionof the anti-hypertensive marketintermsof the dominanttherapies,and
theirclinical andcommercial standing.Unmetneedsare highlightedtoallow acompetitive
understandingof gapsinthe market.
- Analyze the anti-hypertensive pipelineandstratifypipeline therapiesbystage of development,
molecule type andmoleculartarget.
- Considermarketopportunitiesandpotential risksbyexaminingtrendsinhypertensionclinical trial
size,duration,andfailure rate bystage of development,moleculetype,andmechanismof action.
- Predictanti-hypertensive marketgrowthinthe five Asia-Pacificmarketswithepidemiological and
annual cost of therapyforecastsacross India,China,Australia,SouthKoreaand Japan.The forecastswill
provide anunderstandingof howepidemiologytrends,new drugentries,andpatentexpirationswill
influencemarketvalue.
- Identifycommercial opportunitiesinthe anti-hypertensivedealslandscape byanalyzingtrendsin
licensingandco-developmentdeals.
Table of Contents
1.1 Listof Tables7
1.2 Listof Figures7
2 Introduction9
2.1 Disease Introduction9
2.2 Epidemiology10
2.3 Symptoms11

4. 2.4 EtiologyandPathophysiology11
2.5 Diagnosis13
2.5.1 Office orClinicBloodPressure Monitoring14
2.5.2 AutomatedOffice BloodPressure Measurement14
2.5.3 AmbulatoryBloodPressure Monitoring15
2.5.4 Home BloodPressure Monitoring15
2.5.5 MiscellaneousMethods15
2.5.6 Diagnosisof TargetOrgan Damage 15
2.5.7 Diagnosisof HypertensioninPregnancy15
2.6 Prognosis16
2.7 Disease Stage 17
2.8 TreatmentOptions17
2.8.1 TreatmentAlgorithm17
2.8.2 Pharmacological Treatment18
2.8.3 Non-pharmacological Treatment22
3 MarketedProducts24
3.1 AngiotensinIIReceptorAntagonists24
3.1.1 Losartan - Merck & Co 24
3.1.2 Olmesartan - Daiichi Sankyo26
3.1.3 Olmesartan+ Amlodipine+Hydrochlorothiazide - Daiichi Sankyo27
3.1.4 Valsartan - Novartis28
3.1.5 Telmisartan - BoehringerIngelheim29
3.1.6 AzilsartanMedoxomil - Takeda30
3.2 CalciumChannel Blockers31
3.2.1 Amlodipine - Pfizer31

5. 3.3 ReninInhibitors32
3.3.1 Aliskiren - Novartis32
3.4 AngiotensinConvertingEnzyme Inhibitors33
3.4.1 Ramipril - Sanofi 33
3.5 BetaBlockers33
3.5.1 Carvedilol - GlaxoSmithKline 33
3.6 Multiple DrugClassCombinations34
3.6.1 PerindoprilArginine +AmlodipineBesylate - LesLaboratoiresServier34
3.6.2 Amlodipine +Valsartan - Novartis35
3.7 Comparative EfficacyandSafetyof MarketedProducts36
4 Pipeline Analysis38
4.1 Overview 38
4.2 Pipeline byStage of Development,Molecule Type,Route of AdministrationandProgramType 39
4.3 Pipeline byMolecularTarget41
4.4 PromisingPipelineCandidates43
4.4.1 CS-3150 43
5 Clinical Trial Analysis45
5.1 Failure Rate 45
5.1.1 Overall Failure Rate 45
5.1.2 Failure Rate byPhase and Molecule Type 46
5.1.3 Failure Rate byPhase and MolecularTarget47
5.2 Clinical Trial Duration48
5.2.1 Clinical Trial DurationbyMolecule Type 48
5.2.2 Clinical Trial DurationbyMolecularTarget49
5.3 Clinical Trial Size 50

6. 5.3.1 PatientEnrollmentperTrial byMolecule Type,MolecularTargetandStage of Development50
5.3.2 PatientEnrollmentperProductbyMolecule Type,MolecularTargetandStage of Development52
5.4 Competitive Clinical TrialsMetricsAnalysis54
6 Multi-ScenarioForecast56
6.1.1 Geographical Markets56
6.1.2 Asia-PacificMarket56
6.2 India59
6.2.1 TreatmentUse Patterns59
6.2.2 Annual Costof Therapy60
6.2.3 Market Size 60
6.3 China61
6.3.1 TreatmentUse Patterns61
6.3.2 Annual Costof Therapy62
6.3.3 Market Size 63
6.4 Australia64
6.4.1 TreatmentUse Patterns64
6.4.2 Annual Costof Therapy65
6.4.3 Market Size 66
6.5 SouthKorea67
6.5.1 TreatmentUsage Patterns67
6.5.2 Annual Costof Therapy69
6.5.3 Market Size 70
6.6 Japan70
6.6.1 TreatmentUse Patterns70
6.6.2 Annual Costof Therapy71

7. 6.6.3 Market Size 72
7 DriversandBarriers74
7.1 Drivers74
7.1.1 IncreasingAgingPopulationstoIncrease Prevalence 74
7.1.2 IncreasingOverweightandObese Population74
7.1.3 Increase inDailySodiumIntake 74
7.1.4 SedentaryLifestyleorLessPhysical Activity75
7.1.5 HighPrevalence of SmokingandAlcoholism75
7.1.6 DiversifiedHealthcare ReformtoBoostMarketGrowth 76
7.2 Barriers76
7.2.1 WeakPipelineandWidespreadUsage of GenericDrugs76
7.2.2 Non-pharmacological First-LineTreatment76
7.2.3 Lack of Awarenessof the Disease Condition76
8 DealsandStrategicConsolidations77
8.1 LicensingDeals77
8.1.1 DealsbyRegionand Value 77
8.1.2 Numberof Disclosedand UndisclosedDealsbyYear,Aggregate Deal Value 78
8.1.3 Deal Value byStage of Development,Molecule Type,andMolecularTarget79
8.1.4 KeyLicensingDeals81
8.2 Co-developmentDeals82
8.2.1 DealsbyRegionand Value 83
8.2.2 Deal Value byStage of Development,Molecule Type,andMolecularTarget84
8.2.3 Deal Value byStage of Development,Molecule Type,andMolecularTarget84
8.2.4 KeyCo-developmentDeals85
9 Appendix87

8. 9.1 All PipelineDrugsbyStage of Development87
9.1.1 Discovery87
9.1.2 Preclinical 87
9.1.3 Investigational NewDrug/Clinical Trial Authorization-Filed89
9.1.4 Phase I 90
9.1.5 Phase II91
9.1.6 Phase III91
9.1.7 Pre-registration93
9.2 Market Forecaststo 2022 93
9.2.1 Asia-Pacific93
9.2.2 India94
9.2.3 China94
9.2.4 Australia95
9.2.5 SouthKorea95
9.2.6 Japan 96
9.3 Reference 96
9.4 Abbreviations105
9.5 ResearchMethodology107
9.5.1 SecondaryResearch107
9.5.2 MarketedProductProfiles107
9.5.3 Late-Stage PipelineCandidates107
9.5.4 Comparative EfficacyandSafety HeatMap for MarketedandPipelineProducts108
9.5.5 ProductCompetitivenessFramework108
9.5.6 Pipeline Analysis108
9.5.7 ForecastingModel 109

9. 9.5.8 DealsData Analysis110
9.6 Contact Us 110
9.7 Disclaimer110 1.1 Listof Tables
Table 1: Anti-hypertensiveTherapeutics,PrevalenceRate 11
Table 2: Anti-hypertensiveTherapeutics,Definitionsof HypertensionbyOfficeandOut-of-OfficeBlood
Pressure Levels(mmHg)14
Table 3: Anti-hypertensiveTherapeutics,Proposal forOutcome-DrivenReference ValuesforAmbulatory
BloodPressure Measurement(mmHg) 15
Table 4: Anti-hypertensiveTherapeutics,BloodPressureStagesinAdults(mmHg) 17
Table 5: Anti-hypertensiveTherapeutics,CompellingandPossibleContra-indicationsof Anti-
hypertensive Drugs22
Table 6: Anti-hypertensiveTherapeutics,Lifestyle MeasuresandRecommendations23
Table 7: Anti-hypertensiveTherapeuticsMarket,Global,AllPipelineProducts,Discovery,2016 87
Table 8: Anti-hypertensiveTherapeuticsMarket,Global,AllPipelineProducts,Preclinical,2016 87
Table 9: Anti-hypertensiveTherapeuticsMarket,Global,AllPipelineProducts,Investigational NewDrug,
2016 89
Table 10: Anti-hypertensive TherapeuticsMarket,Global,All Pipeline Products,PhaseI,2016 90
Table 11: Anti-hypertensive TherapeuticsMarket,Global,All Pipeline Products,Phase-II,2016 91
Table 12: Anti-hypertensive TherapeuticsMarket,Global,All Pipeline Products,PhaseIII,2016 91
Table 13: Anti-hypertensive TherapeuticsMarket,Global,All Pipeline Products,Pre-registration,2016 93
Table 14: Anti-hypertensive TherapeuticsMarket,Asia-Pacific,MarketForecast,2015-2022 93
Table 15: Anti-hypertensive TherapeuticsMarket,India,MarketForecast,2015-2022 94
Table 16: Anti-hypertensive TherapeuticsMarket,China,MarketForecast,2015-2022 94
Table 17: Anti-hypertensive TherapeuticsMarket,Australia,MarketForecast,2015-2022 95
Table 18: Anti-hypertensive TherapeuticsMarket,SouthKorea,MarketForecast,2015-2022 95
Table 19: Anti-hypertensive TherapeuticsMarket,Japan,MarketForecast,2015-2022 96
Table 20: Abbreviations105 1.2 Listof Figures

10. Figure 1: Anti-hypertensive Therapeutics,Global,HypertensionPrevalence Rate (%),2009-2012 10
Figure 2: Anti-hypertensive Therapeutics,Physiological Mechanismof Renin-Angiotensin-Aldosterone
System13
Figure 3: Anti-hypertensive Therapeutics:BloodPressure MeasurementsandExaminationof aPatientto
DetectHypertension16
Figure 4: Anti-hypertensive Therapeutics,TreatmentAlgorithmof Hypertension18
Figure 5: Anti-hypertensive Therapeutics,CombinationTherapyStrategiesforBloodPressureReduction
21
Figure 6: Anti-hypertensive Market,ComparativeEfficacyandSafetyHeatmapforMarketedProductsfor
the Treatmentof Hypertension37
Figure 7: Anti-hypertensive Market,ComparativeEfficacyandSafetyHeatmapforMarketedProductsfor
Pediatricsforthe Treatmentof Hypertension37
Figure 8: Anti-hypertensive TherapeuticsMarket,Global,Pipeline,2016 40
Figure 9: Anti-hypertensive TherapeuticsMarket,Global, PipelinebyMolecularTarget,2016 42
Figure 10: Anti-hypertensiveTherapeutics,Global,Pipeline byMolecularTargetandStage of
Development,2016 43
Figure 11: Anti-hypertensiveTherapeutics,Global,Average Clinical Trial Failure Rate (%),2016 46
Figure 12: Anti-hypertensiveTherapeutics,Global,Clinical Trial Failure Rate byMolecule Type (%),2006-
2015 47
Figure 13: Anti-hypertensiveTherapeutics,Global,Clinical Trial Failure Rate byMolecularTarget(%),
2006-2015 48
Figure 14: Anti-hypertensiveTherapeutics,Global,Clinical Trial SizeperProductbyStage of
DevelopmentandMolecule Type,2006-2015 49
Figure 15: Anti-hypertensiveTherapeutics,Global,Clinical Trial DurationbyMolecularTarget,2006-2015
50
Figure 16: Anti-hypertensiveTherapeutics,Global,Clinical Trial SizeperTrial byMolecularType,2006-
2015 51
Figure 17: Anti-hypertensiveTherapeutics,Global,Clinical Trial SizeperTrial byMolecularTarget,2006-
2015 52
Figure 18: Anti-hypertensiveTherapeutics,Global,Clinical Trial SizeperProductbyMolecule Type,2006-
2015 53

11. Figure 19: Anti-hypertensiveTherapeutics,Global,Clinical Trial SizeperProductbyMolecularTarget,
2006-2015 54
Figure 20: Anti-hypertensiveTherapeuticsMarket,Global,Comparisonof Average Trial MetricsbyPhase
and Molecule Type 55
Figure 21: Anti-hypertensiveTherapeuticsMarket,Global,Comparisonof Average Trial MetricsbyPhase
and MolecularTarget55
Figure 22: Anti-hypertensiveTherapeuticsMarket,Asia-Pacific,TreatmentPatterns(million) andMarket
Size ($bn),2015-2022 58
Figure 23: Anti-hypertensiveTherapeuticsMarket,India,TreatmentPatterns(million),2015-2022 59
Figure 24: Anti-hypertensiveTherapeuticsMarket,India,AnnualCostof Therapy($),2015-2022 60
Figure 25: Anti-hypertensiveTherapeuticsMarket,India,MarketSize ($bn),2015-2022 61
Figure 26: Anti-hypertensiveTherapeuticsMarket,China,TreatmentPatterns(million),2015-2022 62
Figure 27: Anti-hypertensiveTherapeuticsMarket,China,AnnualCostof Therapy($),2015-2022 63
Figure 28: Anti-hypertensiveTherapeuticsMarket,China,MarketSize ($bn),2015-2022 64
Figure 29: Anti-hypertensiveTherapeuticsMarket,Australia,TreatmentPatterns(million),2015-2022 65
Figure 30: Anti-hypertensiveTherapeuticsMarket,Australia,Annual Costof Therapy($),2015-2022 66
Figure 31: Anti-hypertensiveTherapeuticsMarket,Australia,MarketSize ($bn),2015-2022 67
Figure 32: Anti-hypertensiveTherapeuticsMarket,SouthKorea,TreatmentPatterns(million),2015-2022
68
Figure 33: Anti-hypertensiveTherapeuticsMarket,SouthKorea,Annual Costof Therapy($),2015-2022
69
Figure 34: Anti-hypertensiveTherapeuticsMarket,SouthKorea,MarketSize ($bn),2015-2022 70
Figure 35: Anti-hypertensiveTherapeuticsMarket,Japan,TreatmentPatterns(million),2015-2022 71
Figure 36: Anti-hypertensiveTherapeuticsMarket,Japan,Annual Costof Therapy($),2015-2022 72
Figure 37: Anti-hypertensiveTherapeuticsMarket,Japan,MarketSize ($bn),2015-2022 73
Figure 38: Anti-hypertensiveTherapeuticsMarket,Global,LicensingDealsbyRegionandValue,2006-
2016 78
Figure 39: Anti-hypertensiveTherapeuticsMarket,Global,Numberof DisclosedandUndisclosed
LicensingDealsbyYear,Aggregate Deal Value andAggregate UpfrontPaymentValue,2006-2016 79

12. Figure 40: Anti-hypertensiveTherapeuticsMarket,Global,LicensingDealsbyStage of Development,
Deal Value andUpfrontPaymentValue,2006-2016 80
Figure 41: Anti-hypertensiveTherapeuticsMarket,Global,LicensingDealsbyMolecule Type andStage
of Development,2006-2016 80
Figure 42: Anti-hypertensiveTherapeuticsMarket,Global,LicensingDealsbyMolecularTargetsand
Aggregate Deal Value ($),2006-2016 81
Figure 43: Anti-hypertensiveTherapeuticsMarket,Global,Co-developmentDealsbyRegion andDeal
Value,2006-2016 83
Figure 44: Anti-hypertensiveTherapeuticsMarket,Global,Numberof DisclosedandUndisclosedCo-
developmentDealsbyYear,Aggregate Deal Value andAggregate UpfrontPaymentValue,2006-2016 84
Figure 45: Anti-hypertensiveTherapeutics,Global,Co-developmentDealsbyPhase andMechanismof
Action,2006-2016 85